Product News

Share this article:

FDA approved labeling changes on Vyvance, Shire's ADHD drug, extending the product's efficacy to 13 hours in children 6 to 12. According to a Shire release, the label changes represent the first and only oral ADHD stimulant treatment to have 13-hour postdose efficacy data for pediatric patients including in the labeling. Consumer and professional campaign materials in support of the label changes are currently in the works, according to a spokesperson.


Bayer Diabetes Care launched a new A1C monitor – A1CNow Selfcheck – enabling people with diabetes to check their A1C level at home. The product is now available without a prescription, and provides at-home results within five minutes, according to a statement.

 

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Illumina inks deal with J&J, AstraZeneca, Sanofi

The goal is to develop companion diagnostics to match patients with cancer treatments.

Abbott deal highlights inversion inaction

Political furor over the recent spate of tax inversions is having little influence on how the government chooses its partners.

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.